Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.59 |
| ▸ | THRA | P10827 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | RARB | P10826 | 3/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221522 | 0.97 | TSHR (0.55) | TP53TSHRPLA2G4BTHRATHRB | |
| SCHEMBL15537810 | 0.89 | THRA (0.59) | TP53TSHRTHRATHRB | |
| SCHEMBL7637707 | 0.86 | TP53 (0.66) | TP53TSHRPLA2G4BTHRATHRB | |
| SCHEMBL1984870 | 0.83 | DRD2 (0.56) | TP53THRATHRB | |
| SCHEMBL10932269 | 0.82 | ALDH1A1 (0.61) | TP53TSHRPLA2G4BTHRATHRB | |
| SCHEMBL8477806 | 0.82 | MCHR1 (0.57) | — | |
| SCHEMBL7140622 | 0.80 | THRA (0.55) | THRATHRBRARB | |
| SCHEMBL15172203 | 0.79 | TP53 (0.65) | TP53TSHRPLA2G4BTHRATHRB | |
| SCHEMBL9504858 | 0.79 | THRA (0.57) | THRATHRBRARB | |
| SCHEMBL17203727 | 0.79 | TP53 (0.74) | TP53TSHRPLA2G4BTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | TP53 3997/4885TSHR 2112/4885PLA2G4B 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.